File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project

TitleGlobal impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project
Authors
KeywordsIncidence
Indirect protection
Pneumococcal conjugate vaccines
Pneumococcal meningitis
Serotype replacement
Serotypes
Vaccine impact
Issue Date24-Jan-2025
PublisherW.B. Saunders.
Citation
The Journal of infection, 2025, v. 90, n. 3 How to Cite?
AbstractBackground: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally. Methods: The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally. Site-specific meningitis incidence rate ratios (IRRs) comparing pre-PCV incidence to each year post-PCV10/13 were estimated by age (<5, 5–17 and ≥18 years) using Bayesian multi-level mixed effects Poisson regression, accounting for pre-PCV trends. All-site weighted average IRRs were estimated using linear mixed-effects regression stratified by age, product (PCV10 or PCV13) and prior PCV7 impact (none, moderate, or substantial). Changes in pneumococcal meningitis incidence were estimated overall and for product-specific vaccine-types and non-PCV13-types. Results: Analyses included 10,168 cases <5 y from PCV13 sites and 2849 from PCV10 sites, 3711 and 1549 for 5–17 y and 29,187 and 5653 for ≥18 y from 42 surveillance sites (30 PCV13, 12 PCV10, 2 PCV10/13) in 30 countries, primarily high-income (84%). Six years after PCV10/PCV13 introduction, pneumococcal meningitis declined 48–74% across products and PCV7 impact strata for children <5 y, 35–62% for 5–17 y and 0–36% for ≥18 y. Impact against PCV10-types at PCV10 sites, and PCV13-types at PCV13 sites was high for all age groups (<5 y: 96–100%; 5–17 y: 77–85%; ≥18 y: 73–85%). After switching from PCV7 to PCV10/13, increases in non-PCV13-types were generally low to none for all age groups. Conclusion: Pneumococcal meningitis declined in all age groups following PCV10/PCV13 introduction. Plateaus in non-PCV13-type meningitis suggest less replacement than for all IPD. Data from meningitis belt and high-burden settings were limited.
Persistent Identifierhttp://hdl.handle.net/10722/368178
ISSN
2023 Impact Factor: 14.3
2023 SCImago Journal Rankings: 2.669

 

DC FieldValueLanguage
dc.contributor.authorYang, Yangyupei-
dc.contributor.authorKnoll, Maria Deloria-
dc.contributor.authorHerbert, Carly-
dc.contributor.authorBennett, Julia C.-
dc.contributor.authorFeikin, Daniel R.-
dc.contributor.authorGarcia Quesada, Maria-
dc.contributor.authorHetrich, Marissa K.-
dc.contributor.authorZeger, Scott L.-
dc.contributor.authorKagucia, Eunice W.-
dc.contributor.authorXiao, Melody-
dc.contributor.authorCohen, Adam L.-
dc.contributor.authorvan der Linden, Mark-
dc.contributor.authordu Plessis, Mignon-
dc.contributor.authorYildirim, Inci-
dc.contributor.authorWinje, Brita A.-
dc.contributor.authorVaron, Emmanuelle-
dc.contributor.authorValenzuela, Maria Teresa-
dc.contributor.authorValentiner-Branth, Palle-
dc.contributor.authorSteens, Anneke-
dc.contributor.authorScott, J. Anthony-
dc.contributor.authorSavrasova, Larisa-
dc.contributor.authorSanz, Juan Carlos-
dc.contributor.authorKhan, Aalisha Sahu-
dc.contributor.authorOishi, Kazunori-
dc.contributor.authorNzoyikorera, Néhémie-
dc.contributor.authorNuorti, J. Pekka-
dc.contributor.authorMereckiene, Jolita-
dc.contributor.authorMcMahon, Kimberley-
dc.contributor.authorMcGeer, Allison-
dc.contributor.authorMackenzie, Grant A.-
dc.contributor.authorMacDonald, Laura-
dc.contributor.authorLadhani, Shamez N.-
dc.contributor.authorKristinsson, Karl G.-
dc.contributor.authorKleynhans, Jackie-
dc.contributor.authorKellner, James D.-
dc.contributor.authorJayasinghe, Sanjay-
dc.contributor.authorHo, Pak Leung-
dc.contributor.authorHilty, Markus-
dc.contributor.authorHammitt, Laura L.-
dc.contributor.authorGuevara, Marcela-
dc.contributor.authorGilkison, Charlotte-
dc.contributor.authorGierke, Ryan-
dc.contributor.authorDesmet, Stefanie-
dc.contributor.authorDe Wals, Philippe-
dc.contributor.authorDagan, Ron-
dc.contributor.authorColzani, Edoardo-
dc.contributor.authorCiruela, Pilar-
dc.contributor.authorChuluunbat, Urtnasan-
dc.contributor.authorChan, Guanhao-
dc.contributor.authorCamilli, Romina-
dc.contributor.authorBruce, Michael G.-
dc.contributor.authorBrandileone, Maria Cristina C.-
dc.contributor.authorAmpofo, Krow-
dc.contributor.authorO'Brien, Katherine L.-
dc.contributor.authorHayford, Kyla-
dc.date.accessioned2025-12-24T00:36:41Z-
dc.date.available2025-12-24T00:36:41Z-
dc.date.issued2025-01-24-
dc.identifier.citationThe Journal of infection, 2025, v. 90, n. 3-
dc.identifier.issn0163-4453-
dc.identifier.urihttp://hdl.handle.net/10722/368178-
dc.description.abstractBackground: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally. Methods: The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally. Site-specific meningitis incidence rate ratios (IRRs) comparing pre-PCV incidence to each year post-PCV10/13 were estimated by age (<5, 5–17 and ≥18 years) using Bayesian multi-level mixed effects Poisson regression, accounting for pre-PCV trends. All-site weighted average IRRs were estimated using linear mixed-effects regression stratified by age, product (PCV10 or PCV13) and prior PCV7 impact (none, moderate, or substantial). Changes in pneumococcal meningitis incidence were estimated overall and for product-specific vaccine-types and non-PCV13-types. Results: Analyses included 10,168 cases <5 y from PCV13 sites and 2849 from PCV10 sites, 3711 and 1549 for 5–17 y and 29,187 and 5653 for ≥18 y from 42 surveillance sites (30 PCV13, 12 PCV10, 2 PCV10/13) in 30 countries, primarily high-income (84%). Six years after PCV10/PCV13 introduction, pneumococcal meningitis declined 48–74% across products and PCV7 impact strata for children <5 y, 35–62% for 5–17 y and 0–36% for ≥18 y. Impact against PCV10-types at PCV10 sites, and PCV13-types at PCV13 sites was high for all age groups (<5 y: 96–100%; 5–17 y: 77–85%; ≥18 y: 73–85%). After switching from PCV7 to PCV10/13, increases in non-PCV13-types were generally low to none for all age groups. Conclusion: Pneumococcal meningitis declined in all age groups following PCV10/PCV13 introduction. Plateaus in non-PCV13-type meningitis suggest less replacement than for all IPD. Data from meningitis belt and high-burden settings were limited.-
dc.languageeng-
dc.publisherW.B. Saunders.-
dc.relation.ispartofThe Journal of infection-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectIncidence-
dc.subjectIndirect protection-
dc.subjectPneumococcal conjugate vaccines-
dc.subjectPneumococcal meningitis-
dc.subjectSerotype replacement-
dc.subjectSerotypes-
dc.subjectVaccine impact-
dc.titleGlobal impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project-
dc.typeArticle-
dc.identifier.doi10.1016/j.jinf.2025.106426-
dc.identifier.pmid39864526-
dc.identifier.scopuseid_2-s2.0-85217119857-
dc.identifier.volume90-
dc.identifier.issue3-
dc.identifier.issnl0163-4453-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats